Bioavailability Assessment of Esomeprazole-Syrup 40 mg vs. Nexium 40 mg Under Fasting and Fed Conditions in a Monocentric, Open, Randomized, Crossover Trial

The primary objective of this clinical trial is to evaluate the **bioavailability** of two products containing **esomeprazole** under fasting and fed conditions. The study compares Esomeprazole-Syrup 40 mg (Test) with Nexium 40 mg (Comparator) in healthy volunteers. Understanding the bioavailability of these formulations is clinically relevant as it informs on the absorption and efficacy of the drug, which is crucial for optimizing therapeutic outcomes and ensuring patient safety. No secondary objectives are specified for this trial.

The clinical trial involves **healthy volunteers** with no therapeutic indication, encompassing both male and female participants. The study population includes individuals within the age range of 18 to 65 years. The sponsor has not provided information regarding the total number of participants. The trial population was selected without targeting any vulnerable groups. Lifestyle considerations such as diet, physical activity, or habits have not been specified. Key inclusion or exclusion criteria have not been detailed by the sponsor.

The clinical trial is designed to evaluate the **bioavailability** of two products containing esomeprazole under fasting and fed conditions. This study is a monocentric, open, randomized, single-dose, four-period, crossover trial conducted in healthy volunteers. The trial is categorized as a Phase 3 study, with no therapeutic indication, as it involves healthy participants. The trial is expected to commence recruitment on February 1, 2024, and conclude by March 1, 2024, indicating a short overall duration of approximately one month.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the test product, Esomeprazole-Syrup 40 mg, or the comparator, Nexium 40 mg, under both fasting and fed conditions across four periods. Each period will involve administration of a single dose, with appropriate washout intervals between doses to ensure accurate assessment of bioavailability. The study design ensures that each participant receives both treatments, allowing for direct comparison within the same individual.

Follow-up visits will be scheduled to monitor participants for any adverse events and to collect necessary pharmacokinetic data. The end-of-study visit will occur after the final dosing period, where comprehensive assessments will be conducted to ensure participant safety and to gather final data points. The expected length of participant involvement is approximately one month, aligning with the overall trial duration. Conditions that may lead to early termination from the study include non-compliance with study procedures, withdrawal of consent, or the occurrence of significant adverse events that compromise participant safety.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information, further details about the **experimental medication** and any **non-experimental treatments** used in the study cannot be provided. The trial documentation does not include any additional relevant information about drug administration or participant compliance monitoring.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on February 1, 2024, with an estimated end date of March 1, 2024. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured protocol to ensure the collection and analysis of efficacy data, adhering to the standards expected in a Phase 3 clinical trial. The trial's objective is to evaluate the treatment's effectiveness, but further specifics regarding the endpoints or tools used for efficacy assessment are not provided in the current dataset.